Helping a Healthcare Major Understand Diagnostic Practices in DLBCL

Business Problem

The client wanted to understand how hematologists and HemOncs approach the diagnosis of diffuse large B-cell lymphoma (DLBCL), including the diagnostic methods they rely on and the challenges they encounter in current standard-of-care practices. The objective was to build a clearer picture of prevailing diagnostic practices and use these insights to inform broader business strategy.

What and How we did it

Borderless Access engaged with 100 hematologists and HemOncs across the EU and USA through focused research discussions. The study examined how physicians diagnose DLBCL, the tests they commonly rely on including imaging and tissue or lymph node biopsies and their use of cell-of-origin (COO) classification to better understand the type of lymphoma.

Key Insights

  • Imaging and biopsy remain central to diagnosis: Respondents most commonly identified imaging tests and tissue/lymph node biopsy among the methods used to diagnose DLBCL. 
  • Biopsy was widely reported in patient diagnosis: Most respondents reported that DLBCL patients received a tissue/lymph node biopsy, reinforcing the role of tissue-based diagnosis in current practice.
  • COO classification is part of current diagnostic practice: 70% of respondents reported ordering or conducting COO classification tests for DLBCL patients, indicating meaningful adoption of this approach among the physicians surveyed. 

Client Impact :

The research gave the client a clearer view of prevalent diagnostic methods and physician practice in DLBCL. These insights provided a stronger basis for understanding the current diagnostic landscape and informing business strategy and operations.

Market

UK Flag

UK

Germany Flag

Germany

France Flag

France

Italy Flag

Italy

Spain Flag

Spain

USA Flag

US